Eli Lilly's Phase 3 randomized controlled trial of retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, demonstrated average weight reductions of 28.3% at the highest dose among completers after 80 weeks in adults with obesity or overweight without diabetes. This RCT-level evidence surpasses the 15-21% losses seen in prior pivotal trials of dual agonists like tirzepatide (SURMOUNT-1, n=2,539, double-blind design, Lilly-funded with no major conflicts beyond sponsorship) and single GLP-1 agents such as semaglutide (STEP 1, n=1,961, similar RCT structure). However, the 11% discontinuation rate due to adverse events exceeds the 7% benchmark from Zepbound and Wegovy trials, highlighting a pattern where multi-pathway activation amplifies both efficacy and gastrointestinal side effects. Original STAT coverage underemphasizes long-term adherence barriers and potential muscle loss risks documented in observational follow-ups of GLP-1 users, while overlooking synergies with bariatric surgery outcomes that achieve 25-30% sustained loss but carry perioperative complications. Amid the GLP-1 revolution, retatrutide positions pharmacotherapy as a scalable alternative, yet real-world utility hinges on mitigating tolerability to match surgical durability.